**:Xinhua.
TOKYO, Feb. 22 (Xinhua) -- Potassium competitive acid blockers (P-CAB) are a new class of drugs that inhibit gastric acid secretion, which can be used for reflux esophagitis and Helicobacter pylori infection. A new study in Japan found that people with Helicobacter pylori infection who took P-CAB for a long time after sterilization had a higher risk of stomach cancer compared to those who took another drug.
According to the communiqué recently released by the University of Tokyo and other institutions, Helicobacter pylori infection is one of the main causes of gastric cancer, and the removal of Helicobacter pylori can prevent gastric cancer to a certain extent, but a small number of infected people will still suffer from gastric cancer after sterilization, and the medical community has been exploring the causes of gastric cancer after removing Helicobacter pylori.
Previous sporadic reports have shown that long-term use of proton pump inhibitors (PPIs) that inhibit gastric acid in patients with Helicobacter pylori infection after sterilization will lead to an increased risk of gastric cancer. As a new class of gastric acid inhibitors, the mechanism of action of P-CAB is different from that of PPI. Because P-CAB is very effective in things like reflux esophagitis, doctors sometimes put patients on this medication for a long time.
This study analysed about 5Data on 40,000 H. pylori cleared infected people who were taking P-CAB, PPI, and histamine H2 receptor antagonists (H2RAs) for a long time. The results showed that the cumulative incidence of gastric cancer in the P-CAB group was 236%, which was significantly higher than the cumulative incidence of H2RA in the H2RA taking group122%。At the same time, the incidence of gastric cancer after sterilization will also increase meaningfully with the increase of the dose and time of taking p-CAB. On the other hand, there was no significant difference in the incidence of gastric cancer in the P-CAB group compared with the PPI group.
Related**Published in the journal Clinical Gastroenterology and Hepatology. According to the communiqué, studies based on large-scale data have shown that long-term use of P-CAB in patients infected with Helicobacter pylori after sterilization may increase the risk of gastric cancer, and the risks of using such drugs should be more widely discussed.